Abstract:Macrophages play a key role in maintaining tissue homeostasis, regulating immune responses, and promoting tumor progression.1Locati M. Curtale G. Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity.Annu. Rev. Pathol. 2020; 15: 123-147Crossref PubMed Scopus (546) Google Scholar Dysregulation of macrophage polarization between the pro-inflammatory M1 and anti-inflammatory M2 phenotypes worsens inflammation, leading to the development of inflammatory-related diseases. Investigators have developed numerous strategies to regulate the balance of M1/M2 macrophage ratio and cytokine content, which may serve as a practical approach for reverse inflammatory status for various disease treatments. Exploring novel vectors to genetically regulate macrophages in vitro and in vivo is attractive. The targeted gene delivery to macrophages is a crucial challenge for boosting gene therapeutic efficacy. Incorporating ligands such as mannose and transferrin into gene transfer vectors has significantly improved delivery efficiency toward native macrophages.2Ferkol T. Perales J.C. Mularo F. Hanson R.W. Receptor-mediated gene transfer into macrophages.Proc. Natl. Acad. Sci. USA. 1996; 93: 101-105Crossref PubMed Scopus (160) Google Scholar In addition to these ligand-based approaches, various bacterial and protozoan microorganisms have been used to infect macrophages and establish chronic infections, representing a potential powerful method to transfer therapeutic DNA agents to macrophages in vivo.3Mantovani A. Allavena P. Marchesi F. Garlanda C. Macrophages as tools and targets in cancer therapy.Nat. Rev. Drug Discov. 2022; 21: 799-820Crossref PubMed Scopus (70) Google Scholar,4Vaccaro D.E. Symbiosis therapy: the potential of using human protozoa for molecular therapy.Mol. Ther. 2000; 2: 535-538Abstract Full Text Full Text PDF PubMed Scopus (7) Google Scholar However, utilizing these intracellular microorganisms raises biosafety concerns. To overcome these challenges, in an article recently published in Molecular Therapy - Nucleic Acids, Song et al. developed size-controlled liposomes that encapsulate microRNAs (miR/MT-Lip) to facilitate the M1 to M2 polarization switch and reduce inflammation without deleterious effects on cells.5Park M. Oh H.J. Han J. Hong S.H. Park W. Song H. Liposome-mediated small RNA delivery to convert the macrophage polarity: a novel therapeutic approach to treat inflammatory uterine disease.Mol. Ther. Nucleic Acids. 2022; 30: 663-676Abstract Full Text Full Text PDF PubMed Google Scholar By delivering miR-10a to macrophages, the switch from M1 to M2 macrophages in the uterus suppressed local inflammation, thereby restoring infertility due to uterine inflammation. Compared with other active targeting techniques relying on ligands, such as antibodies or mannose, this size-dependent approach is more feasible in achieving therapeutic goals. The size control is much easier to achieve than the decoration of ligands, which generally require tedious modification processes. Moreover, this approach can reduce biosafety concerns. Overall, this approach shows great promise in boosting macrophage targeting. The reported delivery system, MT-Lip, uses liposomes containing phospholipids and cholesterol as carriers to deliver microRNAs into macrophages. PEI is added to the liposomes to enhance RNA loading capacity and macrophage internalization. The authors also control the size of the liposomes by adjusting the proportion of cholesterol in total lipids. By obtaining larger-sized liposomes (∼1.24 μm), they achieved a higher macrophage-specific internalization rate. The authors tested their delivery system by co-incubating fluorescently labeled microRNA (miRNA) with two different cell lines: HEK293T cells and RAW 264.7 cells. After evaluating cell internalization using fluorescence microscopy and flow cytometry, the authors found that MT-Lip-encapsulated miRNA was specifically internalized by RAW 264.7 cells but not HEK293T cells. In corresponding in vivo experiments, MT-Lip-delivered fluorescent miRNAs had signals only in splenic macrophages, with almost undetectable fluorescent signals in other immune cells such as neutrophils, natural killer (NK) cells, T cells, B cells, dendritic cells (DCs), and peripheral blood mononuclear cells (PBMCs). These findings suggest that MT-Lip can specifically target macrophages, which has great potential for treating macrophage-related diseases. The authors achieved M2 polarization of macrophages at both cellular and in vivo levels using MT-Lip encapsulated with miR-10a (miR-10a/MT-Lip). In RAW 264.7 cells treated with lipopolysaccharide (LPS), miR-10a/MT-Lip converted M1 macrophages into M2 macrophages, as indicated by upregulated expression of related molecular markers. In vivo, the researchers analyzed splenocytes and PBMCs to evaluate macrophage-specific targeting of their miR/MT-Lip in immune cells. They found that miR-10a/MT-Lip specifically targeted macrophages without disturbing other immune cells in the spleen of mice with inflammation induced by LPS. Finally, in a mouse model of Asherman’s syndrome (AS) characterized by sterile inflammation and fibrosis, the therapeutic effects of miR-10a/MT-Lip were evaluated through intravenous injection for several days. The treatment successfully decreased the M1/M2 ratio and increased the number of M2 macrophages without affecting other uterine cell types or immune cells. In addition to miRNAs, long non-coding RNAs (lncRNAs) are a crucial class of non-coding RNAs that have functional significance in various ways, such as influencing chromatin function, modulating stability and translation of cytoplasmic mRNAs, and interfering with signaling pathways through several mechanisms. Recent research has demonstrated that lncRNAs can participate in M1/M2 polarization and possess multifunctional roles in disease progression. For instance, growth-arrest-specific transcript 5 (GAS5) lncRNA overexpression has been observed to inhibit JAK2/STAT3 signaling, thereby promoting M1 polarization.6Chi X. Ding B. Zhang L. Zhang J. Wang J. Zhang W. lncRNA GAS5 promotes M1 macrophage polarization via miR-455-5p/SOCS3 pathway in childhood pneumonia.J. Cell. Physiol. 2019; 234: 13242-13251Crossref PubMed Scopus (49) Google Scholar This phenomenon was recognized in childhood lung inflammation and held significant potential for developing pneumonia-targeting therapeutic strategies. Although Song et al.’s approach is aimed at miRNA delivery, it is suggested that this system could deliver small interfering RNAs (siRNAs) targeting GAS5 lncRNA, and effectively hinder macrophage polarization to M1 by decreasing the amount of lncRNAs and mitigating related inflammatory responses. Moreover, regulating M1/M2 macrophage polarization is applied in various medical scenarios, such as tumor therapy, tissue engineering, and inflammatory diseases. Nanomedicine is developing rapidly in tumor immunotherapy and is expected to break through the bottlenecks and challenges in immunotherapy. Deeply exploiting the role of biomaterials in macrophage action and polarization will significantly accelerate the development of novel macrophage therapies combined with immunomodulatory biomaterials. Applications in different biological scenarios must be accompanied by more relevant basic research. Analysis of cellular or tissue responses to immunomodulatory biomaterials using state-of-the-art high-throughput gene expression profiling can reveal a more complete and more evident interconnection between relevant biochemical signals in tumor immunotherapy, inflammation, and healing processes. Fascinatingly, rapidly developing artificial intelligence (AI) and big data strategies aim to find applications in medical research that combine strategies for cancer nanomedicine and immunotherapy. A shared cloud service platform for analyzing the interaction of immune cells, tissues, and organs can be established and opened in the future. It is worth noting that the phenotypic conversion of macrophages plays a multifaceted role in different diseases or stages of the same disease, as it reflects changes in the body’s immune status. Different macrophage phenotypes can determine the development and outcome of a disease to a considerable extent. Appropriately intervening in the signaling pathways and local microenvironment of macrophage polarization can steer macrophages toward an expected direction for treating diseases. However, M1 macrophages may also exert beneficial effects in some scenarios, such as clearing infections or cancer cells.3Mantovani A. Allavena P. Marchesi F. Garlanda C. Macrophages as tools and targets in cancer therapy.Nat. Rev. Drug Discov. 2022; 21: 799-820Crossref PubMed Scopus (70) Google Scholar,7Alvarez M.M. Liu J.C. Trujillo-de Santiago G. Cha B.H. Vishwakarma A. Ghaemmaghami A.M. Khademhosseini A. Delivery strategies to control inflammatory response: modulating M1-M2 polarization in tissue engineering applications.J. Control. Release. 2016; 240: 349-363Crossref PubMed Scopus (143) Google Scholar Therefore, when using macrophage polarity to treat diseases, it is necessary to consider different diseases and their physiological stages and determine when and how to perform the phenotypic conversion. We are grateful to the National Natural Science Foundation of China (21574136), Guangdong Basic and Applied Basic Research Foundation (2022A1515140073), and the Youth Innovation Promotion Association Program of CAS (2015008). D.W. and J.Z. prepared the original draft, and J.C. reviewed and edited the manuscript. The authors declare no competing interests.

Abstract:Macrophages play a pivotal role at all stages of progression of atherosclerosis. However, the macrophage-targeted treatment of atherosclerosis remains elusive. Recently, macrophage-targeted gene therapy via lipid polymer nanoparticles (NPs) to improve the atherosclerotic plaque stability in mice was reported. Macrophages play a pivotal role at all stages of progression of atherosclerosis. However, the macrophage-targeted treatment of atherosclerosis remains elusive. Recently, macrophage-targeted gene therapy via lipid polymer nanoparticles (NPs) to improve the atherosclerotic plaque stability in mice was reported. Despite the progress on treatment of acute coronary syndromes (ACSs) over the last decades, ACS remains the leading cause of death worldwide.1Mozaffarian D. Benjamin E.J. Go A.S. Arnett D.K. Blaha M.J. Cushman M. de Ferranti S. Després J.P. Fullerton H.J. Howard V.J. et al.American Heart Association Statistics Committee and Stroke Statistics SubcommitteeHeart disease and stroke statistics--2015 update: a report from the American Heart Association.Circulation. 2015; 131: e29-e322Crossref PubMed Scopus (5117) Google Scholar Understanding of the ACS mechanism can advance the combat of atherosclerosis and improve the survival rate. Erosion of plaque is receiving more attention, as recent clinical data indicate about one-third of ACSs are caused by superficial erosion, which does not need urgent intervention.2Quillard T. Franck G. Mawson T. Folco E. Libby P. Mechanisms of erosion of atherosclerotic plaques.Curr. Opin. Lipidol. 2017; 28: 434-441Crossref PubMed Scopus (62) Google Scholar However, conventional rupture of fibrous cap from a thin plaque is more vital and needs urgent care. Standard pharmacologic treatments including statin, aspirin, and antiplatelet agents to decrease the level of low-density lipoprotein have controlled the risk of atherosclerosis to a certain degree, while side effects remain a potential clinical problem. At the early stage of lesion initiation, low-density lipoprotein, the primary source of lipid, accumulates in the intima. The activated endothelial cells produce adhesion molecules that attract circulating monocytes to penetrate into intima. Monocytes differentiate into macrophages after residence in the intima in response to infection or inflammation.3Libby P. Inflammation in atherosclerosis.Arterioscler. Thromb. Vasc. Biol. 2012; 32: 2045-2051Crossref PubMed Scopus (1302) Google Scholar Mediated by macrophages, T lymphocytes and smooth muscle cells (SMCs) are recruited and migrate into the intima. During the progression of the atherosclerotic plaque, SMCs generate matrix molecules to thicken the intimal layer. Programmed cell death of SMCs and macrophages contributes to the development of necrotic core of the plaque.4Libby P. Buring J.E. Badimon L. Hansson G.K. Deanfield J. Bittencourt M.S. Tokgözoğlu L. Lewis E.F. Atherosclerosis.Nat. Rev. Dis. Primers. 2019; 5: 56Crossref PubMed Scopus (310) Google Scholar Failure of clearance of apoptotic cells and the death of foam cells also contribute to the formation of necrotic core. Macrophages produce many factors, such as procoagulant to trigger the thrombosis.5Libby P. Ridker P.M. Maseri A. Inflammation and atherosclerosis.Circulation. 2002; 105: 1135-1143Crossref PubMed Scopus (5525) Google Scholar In addition, macrophages actively take part in lipoprotein ingestion and accumulation by engulfing impaired cells and pathogens and giving rise to plaque growth. Overall, macrophages play a pivotal role in the progression of atherosclerosis (Figure 1). The stability of plaque determines whether atherosclerosis is at high risk. The atherosclerosis is silent when plaque has a thick fibrous cap, which is comprised of macrophages and SMCs that solubilize clotting factors.6Childs B.G. Baker D.J. Wijshake T. Conover C.A. Campisi J. van Deursen J.M. Senescent intimal foam cells are deleterious at all stages of atherosclerosis.Science. 2016; 354: 472-477Crossref PubMed Scopus (415) Google Scholar However, the activated macrophages in atheroma can produce enzymes to degrade the collagen that strengthen the fibrous caps, subsequently leading to lesion rupture and thrombosis. Tabas and colleagues reported that Ca2+/calmodulin-dependent protein kinase γ (CaMKIIγ) in macrophages significantly contributes to the formation of necrotic core and destabilizes the atherosclerosis plaques, while deletion of CaMKIIγ in microphages leads to smaller necrotic core and a thicker fibrous cap.7Doran A.C. Ozcan L. Cai B. Zheng Z. Fredman G. Rymond C.C. Dorweiler B. Sluimer J.C. Hsieh J. Kuriakose G. et al.CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis.J. Clin. Invest. 2017; 127: 4075-4089Crossref PubMed Scopus (35) Google Scholar Given the pivotal role of macrophages in the development of atherosclerosis, macrophage-targeted therapy is becoming a promising way to treat the atherosclerosis.8Flores A.M. Hosseini-Nassab N. Jarr K.U. Ye J. Zhu X. Wirka R. Koh A.L. Tsantilas P. Wang Y. Nanda V. et al.Pro-efferocytic nanoparticles are specifically taken up by lesional macrophages and prevent atherosclerosis.Nat. Nanotechnol. 2020; 15: 154-161Crossref PubMed Scopus (46) Google Scholar Gene therapy is a promising technique to treat diseases by replacing or knocking out a mutated gene or introducing a new gene. Although this technique remains risky, many studies and clinical trials are being conducted for different diseases, such as genetic disorders and cancer. Encouragingly, the U.S. Food and Drug Administration (FDA) has approved the first siRNA nanotherapy, Patisiran, to treat peripheral nerve disease in 2018. One of the most critical challenges for gene therapy is the effective delivery of the gene of interest. Oligonucleotides are easily degraded upon injection into body. Especially, the RNA-based gene drug has worse stability than DNA-based gene drug. To overcome this issue, encapsulation of RNA/DNA into NPs have been developed as a promising way for gene delivery.9Kong N. Tao W. Ling X. Wang J. Xiao Y. Shi S. et al.Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition.Sci Transl Med. 2019; 11: eaay1565Crossref Scopus (49) Google Scholar But gene-based atherosclerosis treatment via macrophage targeting remains elusive. The recent work of Tao et al. developed a small interfering RNA (siRNA) NP platform to target CaMKIIγ, a molecule in lesional macrophages.10Tao W. Yurdagul A. Kong N. Li W. Wang X. Doran A.C. Feng C. Wang J. Islam M.A. Farokhzad O.C. et al.siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice.Sci Transl Med. 2020; 12: eaay1063Crossref PubMed Scopus (2) Google Scholar This siRNA delivery platform shows great promise in overcoming the delivery challenges, such as nuclease degradation, rapid clearance, and poor accumulation in targeting sites. siRNA NPs show excellent stability and siRNA integrity in both buffer and murine serum. Anchoring S2P peptides, which recognize macrophage receptor stabilin-2, on the surface of siRNA NPs significantly enhanced the plaque accumulation and macrophage uptake. Complexation of siRNA with a cationic lipid not only forms a stable NP core but also helps siRNA escape from endosome to interact with the target gene in cytoplasma. By designing siRNA against the macrophage gene Camk2g and depleting the function of CaMKIIγ, the signaling cascade—such as activating transcription factor 6 (ATF6) increment, liver X receptor alpha enhancement (LXRα), and c-Mer protooncogene tyrosine kinase (MerTK) improvement—results in strengthening of the fibrous cap, thus further improving the plaque stability.10Tao W. Yurdagul A. Kong N. Li W. Wang X. Doran A.C. Feng C. Wang J. Islam M.A. Farokhzad O.C. et al.siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice.Sci Transl Med. 2020; 12: eaay1063Crossref PubMed Scopus (2) Google Scholar To test the siRNA NP delivery platform, Tao et al. intravenously injected Dy647-labeled siRNA, S2P0-Dy647-siRNA NPs, and S2P50-Dy647-siRNA NPs into BALB/c mice for pharmacokinetics study.10Tao W. Yurdagul A. Kong N. Li W. Wang X. Doran A.C. Feng C. Wang J. Islam M.A. Farokhzad O.C. et al.siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice.Sci Transl Med. 2020; 12: eaay1063Crossref PubMed Scopus (2) Google Scholar As expected, NP platform improves the circulation half-life time of siRNA to 1.2–1.5 h from 30 min. Targeting ability tests demonstrate that a 2-fold increment of S2P-modified NPs uptake by macrophage was obtained. In the silencing efficiency study, CaMKIIγ decreased by ∼60% and MerTK was significantly enhanced. Furthermore, Ldlr−/− mice with atherosclerotic lesions showed obvious decrease of enzyme in lesional macrophages when injected with S2P50-siCamk2g NPs. Meanwhile, this siRNA NP delivery platform showed no obvious damage to other organs.10Tao W. Yurdagul A. Kong N. Li W. Wang X. Doran A.C. Feng C. Wang J. Islam M.A. Farokhzad O.C. et al.siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice.Sci Transl Med. 2020; 12: eaay1063Crossref PubMed Scopus (2) Google Scholar Overall, this study provides a promising macrophage-targeted siRNA delivery platform for atherosclerosis treatment. Further studies, such as testing in nonhuman primate models, scale-up manufacturing of siRNA NPs and pharmacotoxicology will still need to be carried out before this exciting nanoplatform can be translated into clinic.

Oversized Liposomes Boost Macrophage-Targeted RNA Delivery to Regulate Macrophage Polarity

Mir-182 Targeting Reprograms Tumor-Associated Macrophages and Limits Breast Cancer Progression

Host-functionalization of macrin nanoparticles to enable drug loading and control tumor-associated macrophage phenotype

Abstract 2693: MicroRNA manipulation of macrophage polarization in DLBCL to augment antibody immunotherapy

Macrophage membrane-coated nanovesicles for dual-targeted drug delivery to inhibit tumor and induce macrophage polarization

Macrophage-Targeting DNA Nanomaterials: A Future Direction of Biological Therapy

Glycocalyx-Mimicking Nanoparticles for Stimulation and Polarization of Macrophages via Specific Interactions

Phenotypic Alteration of BMDM In Vitro Using Small Interfering RNA

Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6

Modulating Repolarization of Tumor-Associated Macrophages with Targeted Therapeutic Nanoparticles as a Potential Strategy for Cancer Therapy

Macrophage-Targeted Gene Therapy to Improve the Atherosclerotic Plaque Stability

Macrophage-Engineered Vesicles for Therapeutic Delivery and Bidirectional Reprogramming of Immune Cell Polarization

Harnessing Anti‐tumor and Tumor‐tropism Functions of Macrophages Via Nanotechnology for Tumor Immunotherapy

Efficient and Targeted siRNA Delivery to M2 Macrophages by Smart Polymer Blends for M1 Macrophage Repolarization as a Promising Strategy for Future Cancer Treatment

Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders

Abstract 2751: ENIGMACTM Discovery Platform Enables Gene to Function Target Validation for Macrophage Therapy

Using Hybrid Nanoplatforms to Combine Traditional Anti-Inflammatory Drug Delivery with RNA-Based Therapeutics for Macrophage Reprograming

A Robust Nanoparticle Platform for RNA Interference in Macrophages to Suppress Tumor Cell Migration.

Nanoparticle-enabled concurrent modulation of phagocytosis and repolarization of macrophages for enhanced cancer immunotherapy

A polymeric nanoplatform enhances the cGAS-STING pathway in macrophages to potentiate phagocytosis for cancer immunotherapy

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery